Rimonabant-Induced Persistent Vomiting

German Journal of Psychiatry

Volumn 16, Issue 1, 2013, Pages 49-50

  Praharaj, Samir Kumar ^a   Sarkhel, Sujit ^b  

^a KASTURBA MEDICAL COLLEGE   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Body weight; Nausea; Rimonabant; Vomiting

Indexed keywords

DOMPERIDONE; HALOPERIDOL; LEVOTHYROXINE; RIMONABANT; THYROTROPIN;

ADULT; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; FEMALE; HUMAN; MENTAL DETERIORATION; NAUSEA; OBESITY; PARANOID SCHIZOPHRENIA; PHYSICAL EXAMINATION; VOMITING; WEIGHT REDUCTION;

EID: 84880814317     PISSN: None     EISSN: 14331055     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713
2. Despres JP, Golay A, Sjostrom L, For the Rimonabant in Obesity-Lipids Study Group. Effect of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134
3. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J,Bátkai S, et al. Activation of the peripheral endocanabinoid system in human obesity. Diabetes 2005; 54: 2838-2843
4. Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 2009; 61: 217-224
5. Parker LA, Limebeer CL, Rock EM, Litt DL, KwiatkowskaM, Piomelli D. The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 2009; 97: 121-124
6. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:761-775
7. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, et al. Anti-obesity effect of SR141716, a CB1, receptor antagonist, in dietinduced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R353-354
8. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF,for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006; 368: 1660-1672
9. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397